Skip to content

Vonoprazan/Amoxicillin

    DEA Class; Rx

    Common Brand Names; Voquezna Dual Pak

    • Potassium-Competitive Acid Blockers; 
    • H pylori Agents

    Vonoprazan

    • Potassium-competitive acid blocker (PCAB)

    • Suppresses basal and stimulated gastric acid secretion at secretory surface of gastric parietal cell through inhibition of the H+,K+-ATPase enzyme system in a potassium-competitive manner

    • Because this enzyme is regarded as the acid (proton) pump within the parietal cell, vonoprazan has been characterized as a type of gastric proton-pump inhibitor, as it blocks the final step of acid production

    • Does not require activation by acid; may selectively concentrate in parietal cells in both resting and stimulated states

    • Binds to active proton pumps in noncovalent and reversible manner

    Amoxicillin

    • Ampicillin derivative; elicits antibacterial effect by binding to penicillin-binding proteins and inhibiting biosynthesis of cell wall

    Indicated for treatment of Helicobacter pylori (H pylori) infection

    Known hypersensitivity to any component – vonoprazan, or amoxicillin (or other beta-lactam antibacterials [eg, penicillins, cephalosporins])

    Rilpivirine-containing products, owing to inhibition of gastric pH by vonoprazan

    • Diarrhea (5.2%)
    • Abdominal pain (2.6%)
    • Vulvovaginal candidiasis (2%)
    • Nasopharyngitis (2%)
    • Headache (1.4%)
    • Hypertension (1.1%)
    • Blood and lymphatic system disorders: Anemia, leukocytosis, leukopenia, neutropenia
    • Cardiac disorders: QT prolongation, tachycardia
    • Eye disorders: Orbital edema
    • Gastrointestinal disorders: Abdominal distention, constipation, dry mouth, duodenal polyp, duodenal ulcer, dyspepsia, flatulence, gastric ulcer, gastroesophageal reflux disease, hematochezia, large intestine polyp, nausea, rectal polyp, stomatitis, tongue discomfort, vomiting
    • General disorders and administration site conditions: Fatigue, pyrexia
    • Immune system disorders: Drug hypersensitivity
    • Infections and infestations: Anal fungal infection, gastrointestinal viral infection, oral fungal infection, pneumonia, tongue fungal infection, upper respiratory tract infection, urinary tract infection, viral infection
    • Investigations: Liver function test abnormal
    • Metabolism and nutrition disorders: Decreased appetite
    • Musculoskeletal system: Bone fracture
    • Nervous system disorders: Ageusia, dizziness, tension headache
    • Psychiatric disorders: Anxiety, depression, insomnia
    • Renal and urinary disorders: Renal hypertrophy, tubulointerstitial nephritis
    • Reproductive system and breast disorders: Vaginal discharge
    • Respiratory, thoracic, and mediastinal disorders: Cough, nasal polyps, oropharyngeal pain
    • Skin and subcutaneous tissue disorders: Dermatitis, dry skin, rash
    • Dysgeusia (0.6%)

    Serious and occasionally fatal hypersensitivity reactions (eg, anaphylaxis, anaphylactic shock, rash, erythema multiforme, and Henoch-Schonlein purpura) reported with components; discontinue immediately and institute appropriate treatment if hypersensitivity occurs

    Severe cutaneous adverse reactions (SCAR), including SJS and TEN, reported with all components; additionally, DRESS and AGEP have been reported with amoxicillin; discontinue at first signs of SCAR

    Clostridioides difficile–associated diarrhea (CDAD) reported with acid-suppressing therapies and nearly all antibacterial agents; CDAD must be considered in all patients who present with diarrhea following antibacterial use; careful medical history necessary since CDAD reported to occur over 2 months after administration of antibacterial agents; if CDAD confirmed, discontinue, and implement appropriate management

    High percentage of patients with mononucleosis who receive amoxicillin develop an erythematous skin rash; avoid in patients with mononucleosis

    Prescribing this regimen in absence of proven or strongly suspected bacterial infection or prophylactic indication is unlikely to provide benefit and increases risk for drug-resistant bacteria

    Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acidity; increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors; assess CgA levels at least 14 days after treatment, and consider repeating test if initial CgA levels are high

    Glucose tests: High urine concentrations of amoxicillin may cause false-positive results when using glucose tests based on the Benedict copper reduction reaction that determines the amount of reducing substances, like glucose, in the urine; use enzymatic glucose oxidase reactions instead while taking amoxicillin

    Available data from pharmacovigilance reports with vonoprazan use in pregnant females are not sufficient to evaluate for drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes

    There are no data regarding the presence of vonoprazan in human milk, the effects on the breastfed infant or the effects on milk production

    Data from published clinical lactation study indicate that amoxicillin is present in human milk

    Adults

    Dose: vonoprazan 20 mg PO BID plus amoxicillin 1000 mg PO TID x 14 days

    Pediatric

    Safety and efficacy not established

    Vonoprazan/amoxicillin

    copackaged tablets and capsules

    • tablets: vonoprazan 20 mg
    • capsules: amoxicillin 500 mg
    • Carton contains 14 daily administration packs for twice daily dosing of vonoprazan and 3 times daily dosing of amoxicillin